JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beyer, T.
Right arrow Articles by Stattaus, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beyer, T.
Right arrow Articles by Stattaus, J.
Journal of Nuclear Medicine Vol. 46 No. 3 429-435
© 2005 by Society of Nuclear Medicine


Clinical Investigations

Optimized Intravenous Contrast Administration for Diagnostic Whole-Body 18F-FDG PET/CT

Thomas Beyer, PhD1, Gerald Antoch, MD2, Andreas Bockisch, MD, PhD1 and Joerg Stattaus, MD2

1 Department of Nuclear Medicine, University Hospital Essen, Essen, Germany
2 Department of Diagnostic and Interventional Radiology, University Hospital Essen, Essen, Germany

Standard application of CT intravenous contrast agents in combined PET/CT may lead to high-density artifacts on CT and attenuation-corrected PET. To avoid associated diagnostic pitfalls, we designed and compared different intravenous contrast injection protocols for routine whole-body PET/CT. Methods: Whole-body PET/CT included a topogram and a single spiral CT scan (2-row) with or without intravenous contrast, followed by an emission scan. The CT scan was used for attenuation correction of the emission data. Four groups of 10 whole-body PET/CT referrals each were investigated: (A) no intravenous contrast agent, (B) biphasic injection (90 and 50 mL at 3 and 1.5 mL/s, respectively) of intravenous contrast (300 mg/mL iodine) and CT in the craniocaudal direction with a 30-s delay, (C) triple-phase injection (90, 40, and 40 mL at 3, 2, and 1.5 mL/s, respectively) in the craniocaudal direction with a 50-s delay, and (D) dual-phase injection (80 and 60 mL at 3 and 1.5 mL/s, respectively) in the caudocranial direction with a 50-s delay. CT image quality was assessed on a scale from 1 to 3, and CT and attenuation-corrected PET images were reviewed separately for contrast-induced artifacts. Results: Average CT image quality was poorest for protocol A (1.0) but improved to 2.8 when using intravenous contrast agents (protocols B–D). Only protocols B and C resulted in contrast-induced image artifacts that were limited to the thorax. The most homogeneous intravenous contrast enhancement without high-density image artifacts on either CT or PET after CT-based attenuation correction was achieved with protocol D. Conclusion: Dual-phase intravenous contrast injection and CT in the caudocranial direction with a 50-s delay yields reproducible high image quality and is now used routinely for combined diagnostic PET/CT at our hospital.

Key Words: combined PET/CT • CT intravenous contrast agent • image quality • image artifacts




This article has been cited by other articles:


Home page
JNMHome page
R. Boellaard
Standards for PET Image Acquisition and Quantitative Data Analysis
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 11S - 20S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. J. Gollub, R. Hong, D. M. Sarasohn, and T. Akhurst
Limitations of CT During PET/CT
J. Nucl. Med., October 1, 2007; 48(10): 1583 - 1591.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
D. D. Purcell, F. V. Coakley, B. L. Franc, R. A. Hawkins, S. E. Boddington, and B. M. Yeh
Anterior Layering of Excreted 18F-FDG in the Bladder on PET/CT: Frequency and Cause
Am. J. Roentgenol., August 1, 2007; 189(2): W96 - W99.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
P Veit-Haibach, G Antoch, T Beyer, H Stergar, R Schleucher, E A M Hauth, and A Bockisch
FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy
Br. J. Radiol., July 1, 2007; 80(955): 508 - 515.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
A C Pfannenberg, P Aschoff, K Brechtel, M Muller, M Klein, R Bares, C D Claussen, and S M Eschmann
Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging
Br. J. Radiol., June 1, 2007; 80(954): 437 - 445.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
T. Z. Wong, E. K. Paulson, R. C. Nelson, E. F. Patz Jr., and R. E. Coleman
Practical Approach to Diagnostic CT Combined with PET
Am. J. Roentgenol., March 1, 2007; 188(3): 622 - 629.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
H. Kuehl, P. Veit, S. J. Rosenbaum, A. Bockisch, and G. Antoch
Can PET/CT Replace Separate Diagnostic CT for Cancer Imaging? Optimizing CT Protocols for Imaging Cancers of the Chest and Abdomen
J. Nucl. Med., January 1, 2007; 48(1_suppl): 45S - 57S.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. Rodriguez-Vigil, N. Gomez-Leon, I. Pinilla, D. Hernandez-Maraver, J. Coya, L. Martin-Curto, and R. Madero
PET/CT in Lymphoma: Prospective Study of Enhanced Full-Dose PET/CT Versus Unenhanced Low-Dose PET/CT
J. Nucl. Med., October 1, 2006; 47(10): 1643 - 1648.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Brechtel and T. Beyer
Reply: Adequate Evaluation of Image Registration in Hybrid PET/CT.
J. Nucl. Med., September 1, 2006; 47(9): 1557 - 1558.
[Full Text] [PDF]


Home page
JNMHome page
Y. S. Jhanwar and D. J. Straus
The Role of PET in Lymphoma
J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K. Brechtel, M. Klein, M. Vogel, M. Mueller, P. Aschoff, T. Beyer, S. M. Eschmann, R. Bares, C. D. Claussen, and A. C. Pfannenberg
Optimized Contrast-Enhanced CT Protocols for Diagnostic Whole-Body 18F-FDG PET/CT: Technical Aspects of Single-Phase Versus Multiphase CT Imaging
J. Nucl. Med., March 1, 2006; 47(3): 470 - 476.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Leboulleux, C. Dromain, G. Bonniaud, A. Auperin, B. Caillou, J. Lumbroso, R. Sigal, E. Baudin, and M. Schlumberger
Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 920 - 925.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. Beyer, A. Bockisch, H. Kuhl, and M.-J. Martinez
Whole-Body 18F-FDG PET/CT in the Presence of Truncation Artifacts
J. Nucl. Med., January 1, 2006; 47(1): 91 - 99.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
H. Schoder, H. W.D. Yeung, and S. M. Larson
CT in PET/CT: Essential Features of Interpretation
J. Nucl. Med., August 1, 2005; 46(8): 1249 - 1251.
[Full Text] [PDF]


Home page
JNMHome page
G. Brix, U. Lechel, G. Glatting, S. I. Ziegler, W. Munzing, S. P. Muller, and T. Beyer
Radiation Exposure of Patients Undergoing Whole-Body Dual-Modality 18F-FDG PET/CT Examinations
J. Nucl. Med., April 1, 2005; 46(4): 608 - 613.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.